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ABSTRACT 
The world is currently battling a pandemic disease that is spreading rapidly due to severe acute respiratory syndrome coronavirus 
19 (SARS-CoV-2) that belongs to a family of coronaviruses. As per 20th December 2020, more than 77 million people have 
been infected with more than 1.7 million fatality cases reported worldwide. In response to this Pandemic, several efforts are 
being put in place to identify possible remedies, including therapeutic agents and against this virus. Currently, there is no 
approved vaccine or drugs against the virus, even though some countries such as Japan have approved the investigational drug 
Remdesivir as a coronavirus regimen. Other drugs such as chloroquine, which is widely used in treatment, remains controversial 
as there is no scientific evidence that establishes its effectiveness in the control of SARS-COV-2. This review constitutes a 
summary of SARS-COV-2 genomics and evolutionary relationship to other viruses, pathogenicity, transmission as well as efforts 
that have been made in the development of drugs and vaccines against this virus. We envisage that this review will provide an 
insightful and extensive coverage on the virus as well as support researchers in vaccine development and effective treatment 
protocol. 
 
Keywords: Coronavirus, COVID-19, SARS-COV-2, pandemic, acute pneumonia   
 
*Author for correspondence: Email: patrick.ntagereka@gmail.com;   Tel: +243991106338 
 
Received: November, 2020; Accepted: December, 2020 
 
Abstracted by: 
Bioline International, African Journals online (AJOL), Index Copernicus, African Index Medicus (WHO), Excerpta medica 
(EMBASE), CAB Abstracts, SCOPUS, Global Health Abstracts, Asian Science Index, Index Veterinarius 
INTRODUCTION 
 
Acute respiratory infections (ARI) constitute the most 
common diseases in humans with a high morbi-mortality rate, 
mostly in children. Clinical manifestations usually range from 
mild, uncomplicated upper respiratory tract illness to severe 
lower respiratory tract infections such as pneumonia, 
bronchiolitis, and croup (Treanor, 2017). Most etiological 
agents of ARI are viruses (Treanor, 2017). To date, eight 
human respiratory viruses including adenovirus (ADV), 
bocavirus (BoV), coronavirus (CoV), metapneumovirus 
(MPV), parainfluenza virus (PIV), respiratory syncytial virus 
(RSV), rhinovirus (RV), and severe acute respiratory 
coronavirus (SARS-CoV) are associated with ARI (Walker et 
al., 2013). For this review, we focus particularly on the severe 
acute respiratory associated with coronaviruses, which have 
recently emerged and threatened the public health worldwide.  
 The coronaviruses belong to the Coronaviridae family, 
which consists of enveloped, positive single-stranded RNA 
viruses with a large genome ranging between 26-31Kb in 
length (Su et al., 2016). They cause diverse symptoms, 
including pneumonia, fever, breathing difficulty, and lung 
infection in humans (WMHC, 2020) and other mammals 
(Adhikari et al., 2020). Interest in coronavirus, particularly on 
the coronavirus genetic diversity and genomics, has increased 
worldwide just after the SARS epidemic from southern China 
in 2003 (Liu et al., 2005). To date, 7 CoVs species are known 
to infect humans; they include two αCoV (HCoV-229E and 
HKU-NL63) and four βCoV (HCoV-OC43, HCoV-HKU1, 
SARS-CoV, and MERS-CoV) and recently, the SARS-CoV-
2 (2019 novel coronavirus disease (COVID-19)) reported in 
Wuhan, China in December 2019 (Li et al., 2020). Even 
though SARS-CoV-2 bears similarity with other 
coronaviruses in clinical manifestation and genome, each 
strain has distinct additional ORFs (Adhikari et al., 2020).  
 We report the pathogenesis, transmission patterns, and 
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as potential drug and vaccine targets. We envisage that this 
review will provide an insightful overview of the novel virus 
and assist as a reference in management efforts against the 
COVID19. 
 
SEARCH METHOD AND SELECTION OF ARTICLES  
The literature search was conducted through mainly the 
PubMed, Web of Science, Science Direct, BMJ, Oxford as 
well as THE LANCET journals using the following key 
words: COVID-19, Coronavirus, SARS-CoV-2, SARS-CoV-
2 genome and COVID-19 drug discovery in order to retrieve 
recent articles published on coronavirus pandemic worldwide. 
In addition, we considered findings obtained through hand 
searching in WHO reports. After checking the reference list of 
each study found via the above methods, any old data 
presenting inappropriate topics which were not in accordance 
to the purpose of this studies were excluded.  
 
DATA COLLECTION AND ANALYSIS 
A total of five review authors were available to screen both 
the title and abstracts of all the retrieved studies in order to 
identify and remove studies which do not meet the inclusion 
criteria. The entire text was read for all retained articles and 
final agreement was taken for each article. The same five 
review authors who selected independently the articles 
extracted also the data using a form containing the study 
characteristics such as the pathogenesis of SARS-CoV-2, 
2019 novel coronavirus, evolution of coronavirus, drug 
discovery against COVID-19 and proteome and efforts on 
SARS-CoV-2 vaccine development. For any difference of 
opinion, all the review authors were consulted and discussed 
to provide conclusion after completion of data selection. 
 
CURRENT STATUS OF KNOWLEDGE 
 
Severe acute respiratory syndrome coronaviruses (SARS-
CoV): Severe acute respiratory syndrome (SARS) caused by 
novel SARS-associated coronavirus (SARS-CoV) was 
considered as a natural catastrophe that affected China in the 
twenty-first century (Peiris et al., 2003). The epidemic 
features of this disease had initially emerged as human 
pneumonia- associated disease and were reported for the first 
time in November 2002 in Southern China, particularly in 
Guangdong province (WHOa, 2003). Following its 
introduction in Hong Kong by an infected physician from the 
mainland in mid-February 2003, the virus has spread quickly 
to various countries over the world (more than 30 countries) 
through international air travel involving more than 8000 
persons worldwide with 774 deaths reported and a fatality rate 
of 9.6% (WHOb, 2003). Due to the rapid spread and increase 
of this uncommon infection, the World Health Organization 
(WHO) designated this condition severe acute respiratory 
syndrome” (SARS). Infected patients present main flu-like 
symptoms such as fever, chills, cough, and malaise. 
Transmission between humans occurs by direct contact, 
droplet, as well as airborne routes.  
 Additionally, the identification of the viral genome in 
both fecal and urine samples indicated additional routes of 
transmission. Equally, several animals such as civet cats, 
raccoon dogs, and different bat species have been identified to 
be natural reservoirs (Peiris et al., 2003). like the other 
coronaviruses, the SARS-CoV membrane proteins, including 
the major proteins S (Spike) and M (membrane), which are 
placed into Golgi intermediate compartment of the 
endoplasmic reticulum (ER), while the RNA plus strands 
assemble with the N (nucleocapsid) protein (Guan et al., 
2004). Because of the high prevalence, widespread and 
distribution of coronaviruses, the high genetic diversity, 
regular recombination of their genomes as well as human-
animal interaction, novel coronaviruses are predicted to 
emerge occasionally in humans (Cui et al., 2019). 
 Since December 2019, several local health facilities 
reported a high number of patients with pneumonia of 
unknown causative agents in Wuhan, a large city located in 
central China with about 11 million habitats (WMHC, 2020). 
A study on the epidemiology and etiology was quickly carried 
out by the China CDC in Wuhan and reported a respiratory 
disease spreading from one person to another caused by a 
novel (new) coronavirus. This report largely advised the 
decision by the World Health Organization (WHO) on 29 
December 2019 to use the term 2019 novel coronavirus to 
refer to the coronavirus responsible for lower respiratory tract 
infection in patients in Wuhan. The disease was given the 
official designation as coronavirus disease (COVID-19) (Li et 
al., 2020). 
 
The 2019 novel coronavirus (SARS-COV-2): Severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), is the 
causative agent of coronavirus disease 2019 (COVID-19), 
typical viral pneumonia responsible for the recent unusual 
outbreak in Wuhan. After the Middle East respiratory 
syndrome coronavirus (MERS-CoV) and severe acute 
respiratory syndrome coronavirus (SARS-CoV) in the twenty-
first century, the emergence of SARS-CoV-2 has been marked 
as the third incidence of a highly pathogenic coronavirus 
among the human population (Li et al., 2020). The disease has 
spread quickly and widely since its initial report in Wuhan, 
China, since December 2019, with a high mortality rate, 
especially among aged people from above 60 years old (Zhou 
et al., 2020).  
 Typically, the clinical and paraclinical signs of COVID-
19 in infected patient occurs between the first day of exposure 
to 14 days post-exposure with the majority of patients 
presenting symptoms such as high fever, cough, fatigue, 
difficulty in breathing, irritation of the throat and headache 
(Guan et al., 2020). Additionally, respiratory symptoms such 
as high levels of pro-inflammatory cytokines in plasma, as 
well as higher leukocyte numbers, have been reported (Jin et 
al., 2020). As a main respiratory system targeting virus, the 
most pathogenic lesions for COVID-19 infection include 
severe pneumonia, joined together with the incidence of 
ground-glass opacities, and acute cardiac injury (Jin et al., 
2020). Moreover, few patients fall in critical condition by 
developing acute respiratory distress syndrome, respiratory 
failure, multiple organ failure, and deaths (Huang et al., 2020). 
 
SARS-CoV-2 pathogenesis: Several scientists in China and 
in the world discovered that SARS-CoV-2, just like SARS-
CoV, requires the angiotensin-converting enzyme 2 (ACE2). 
This enzyme plays an important role as a receptor to enter cells 
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(Zhou et al., 2020). Previously, Raj et al. (2013) identified 
Dipeptidyl peptidase 4 (DPP4, which is also named CD26). 
This MERS-CoV functional receptor from spike protein was 
purified with DPP4 from susceptible cells of Huh-7 lysates. 
This protein (MERS-CoV) can attach to DPP4 from several 
species, including humans. This explains and promotes the 
theory of transmission to humans and other species, and 
infection of cells from a large number of species (Barlan et al., 
2014). 
 The similarity of SARS-CoV and MERS-CoV 
pathogenesis can be inferred to SARS-CoV-2 to recognize 
COVID-19, as its pathogenesis is still under investigation and 
remains poorly understood to date. On approximately 30% of 
the genome, four structural proteins are encoded. These 
proteins included: envelope protein (E), spike protein (S), 
membrane protein (M), and nucleocapsid protein (N) as well 
as several accessory proteins with unknown functions. For 
most coronaviruses, the corresponding receptors on target 
cells are mainly recognized through S proteins on their surface 
(Fig. 1). 
 The first step in infection is the entry of the virus into the 
host cells (Wang et al., 2020). The SARS-CoV-2 entry into 
the cell of the host is facilitated by envelope spike 
glycoprotein (S), which binds by membrane fusion to the 
plasma membrane and the virus via the receptor ACE2 and 
CD209L (a lectin named L-SIGN) (Wu et al., 2020). The virus 
might enter through the mucous membranes, particularly nasal 
and larynx mucosa, then passes to the lungs through the 
respiratory tract (Lu et al., 2020). Target organs that express 
ACE2, such as the lungs, heart, renal system, and 
gastrointestinal tract, will be affected by the virus. The second 
step in the infection attack starts by changing patient’s state to 
worsen about 7 to 14 days after onset (Adhikari et al., 2020). 
For the mechanism of COVID-19 treatment and prevention, it 
is important to understand the virus pathogenicity (Li et al., 
2020). When the virus enters the cells via the MHC I 
molecules and sometimes MHC II, the antigen presentation 
cells (APC) are activated (Fig. 1). 
 
Genetic structure of SARS-CoV-2 genome: SARS-CoV-2 
genome has six major open-reading frames (ORFs) that are 
common to coronaviruses. In addition to these ORFs, SARS-
CoV-2 encodes accessory genes in four more ORFs bringing 
a total to at least ten ORFs (Fig. 2). The first open reading 
frame (ORF1a/b), which covered approximatively two-thirds 
of the RNA is translated into 2 big proteins. The complex of 
viral replicase transcriptase is formed by the PP1a and PP1ab 
polyproteins of MERS-CoV and SARS-CoV that are 






The life cycle of SARS-CoV-2in human lung cells. Transmission of the virus is by droplets during sneezing and coughing 
followed by infiltration to the upper respiratory tract. S-glycoprotein binds to human ACE2 receptors, the fusion of viral and 
host’s membrane occurs and the viral RNA is released into the cell cytoplasm. Transcription and translation of the viral 
RNA begins and finally, the assembly and release of infectious viral particles through exocytosis mark the end of the cycle. 
(Adnan et al., 2020). 
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Figure 2:  
The genome structure and encoded proteins of SARS coronavirus 2. The yellow tracks represent the genes (CDSs) while the 
lower track (green and brown) represents individual protein-coding domains. Highlighted (in brown) proteins play major 
roles in viral replication, assembly, virulence, and morphogenesis. (Zhang Yang Lab, 2020). 
 
 
The rough endoplasmic reticulum is the origin of these 
nonstructural proteins rearrange membranes. The 
transcription and replication of the SARS virus occur in 
double-membrane vesicles (DeLano, 2020).  Recently some 
studies showed that the SARS-CoV nucleotide sequences 
share less than 80% identity with other 2019-nCoV genomes 
(Li et al., 2020; Zhou et al., 2020). However, the protein 
sequencing of seven conserved regions in the open reading 
frame 1ab used the classification and similarities of 
coronaviruses showed 94.4% of identity between SARS-CoV 
and the novel 2019-nCoV. This high similarity showed that 
these two viruses belong to the same SARSr-CoV species (Raj 
et al., 2013).  
 Among all studied RNA viruses, CoV has the longest 
genome with about 32 to 43% of GC contents with several 
small open reading frames within and between conserved 
regions in various genes and downstream to the nucleocapsid 
protein in many lineages of coronavirus. Genes for the major 
structural proteins in all coronaviruses occur in the '5’-'3’order 
direction (Su et al., 2016). The '5’UTR and '3’UTR are 
involved in inter-and intramolecular interactions. This region 
plays a major role in RNA-RNA interactions and cellular 
proteins and virus binding.  
 The length of the encoded proteins are 29844bp (7096aa) 
for COVID-19, 29751bp (7073aa) for SARS-CoV, and 
30119bp (7078) for MERS-CoV at the 5’ end in the first open 
reading frame (ORF-Pb1ab) of the genome.  From a recent 
comparative genomic study, the visualized difference was 
1273aa for COVID-19, 21493aa for SARS-CoV, and 1270aa 
in MERS-CoV when the spike protein compared among the 
tree beta coronaviruses. Indeeed, the SARS-CoV-2 genome 
was 79% similar to SARS-CoV and 50% similar to MERS-
CoV. The arrangement of nucleocapsid protein (N), an 
envelope protein (E), and membrane protein (M) among beta 
coronaviruses is different (Mousavizadeh and Ghasemi, 
2010). 
 
Evolution of coronavirus: The novel coronavirus (SARS-
Cov2) clusters in Sarbecovirus subgenus, Beta coronavirus 
genus and family Coronavirus. The origin of SARS-Cov2 is 
yet to be conclusively defined even though several studies 
have reported a close similarity to coronaviruses derived from 
bats (Li et al., 2020; Vijaykrishna et al., 2007). The majority 
of studies, are arriving at the same conclusion on the 
possibility of interspecies transmission of coronaviruses.  
Recently, Li et al., (2020) identified coronaviruses strains 
from five wild animals that share a close nucleotide sequence 
similarity with the novel coronavirus. For phylogeny, to infer 
the genetic relationship between different coronavirus 
isolates, we aligned a total of 27-genomic sequences of 
coronaviruses from different regions retrieved from the 
GenBank database. All isolates from fifteen random 
representative samples collected in 2020 from different 
regions clustered in a single clade. 
 Our phylogenetic tree showed a close evolutionary 
relationship to coronaviruses derived from bats, and an even 
closer relationship to pangolin coronaviruses (Fig. 3). Besides 
this being in agreement with Zhang et al., (2020) on the 
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observed closer relationship between spike protein amino acid 
sequences from SARS-COV-2 and pangolin coronavirus 
compared to bats, it is interesting to note that previous SARS 
coronaviruses derived from human are clustering way distant 
from the novel SARS-COV-2. Another notable observation is 
in the bat coronaviruses evolution, where previous isolates do 
not fall under the same clade as the recent (2020) isolates and 
are clustering further away from the novel SARS-COV-2. 
 
PROGRESS IN DRUG DISCOVERY AGAINST COVID-
19 PROTEOME: 
Viral proteins are important components in drug development 
pipelines. They can be the main drug targets or modulators of 
the drug targets and their activities. To this end, up to nine 
antiviral drugs, including Remdesivir, favipiravir, 
tocilizumab, camostat mesylate, hydroxychloroquine, 
ritonavir, and lopinavir are in drug pipelines as the world race 
against the novel coronavirus (Wu et al., 2020; Arya et al., 
2020). The sad tale is that no single drug has been identified 
so far to effectively work against the virus, with the current 
treatment strategy being the management of associated 
COVID symptoms. For this review, we compile reports on the 
efforts and status of drugs targeting these proteins. 
 
Nonstructural protein1: Towards the '5’UTR end of the 
genome (Fig. 2) is a region that encodes a 35kDa, 
nonstructural protein1 (nsp1) common among 
alphacoronaviruses and beta coronaviruses plays a role in 
inhibition the host translation through interaction with the 
small ribosome subunit (Shen et al., 2019).  Mutagenesis 
studies have shown that this interaction leads to the formation 
of a 40S ribosome-nsp1 complex, which aids in the 
degradation of host mRNA through endonucleolytic cleavage 
close to '5’UTR region of the untranslated capped transcript 
(Ahmed et al., 2020;  Kamitani et al., 2009) The viral mRNA 
is guarded against this endonucleolytic degradation as they 
possess a 5′-end leader sequence that serves as protection 
(Subissi et al., 2014).  Experimental evidence also points to 
the role of this protein in inhibition of the beta interferon (β-
IFN) expression and suppression of the host innate immune 
activities (Narayanan et al., 2008). 
 In pigs, nsp1 from transmissible gastroenteritis virus 
(TGEV), a member of coronavirus family was reported as an 
essential virulence determinant, and due to a conserved motif 
consisting of up to 95 amino acids, this protein has been 
identified as a potential drug target (Shen et al., 2019). The 
SARs attenuated recombinant coronavirus vaccine with a 
deletion of nsp1 homolog in mouse hepatitis virus (MHV) 
have so far been tested and have shown the ability to induce 
cytotoxic T cell responses at a low dose (Züst et al., 2007). 
Equally, drugs that are conventionally used for bacterial 
therapies including tetracycline, piperacillin, streptomycin, 
cefpiramide, lymecycline, platycodin D have been shown to 
strongly bind to Nsp1, Nsp3c, and ORF7a (Wu et al., 2020). 
Unlike nsp1, whose role is profound, nonstructural protein2 




Figure 3:  
The phylogenetic relationship among SARS-CoV-2 and other coronaviruses in pangolin, bats, and humans. Red-colored 
labels represent fifteen (15) different 2020 isolates of SARS-COV-2. Blue and brown coded labels denote coronaviruses 
from bats and pangolins respectively, the closest relatives to SARS_COV-2. Middle East respiratory syndrome coronavirus 
(MERS-CoV) Refseq (NC_019843) was used as outgroup. The percentage of replicate trees in which the associated taxa 
clustered together in the bootstrap test (1000 replicates) are shown next to the branches. The MP tree was obtained using the 
Subtree-Pruning-Regrafting (SPR) algorithm with search level 1 in which the initial trees were obtained by the random 
addition of sequences (10 replicates). Evolutionary comparisons were contacted using MEGAX. (Li et al., 2020). 
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Papain-like proteinase (PLpro): Also called nsp3 is 
associated with the cleavage activity of the “replicase” n-
terminal (Xiao et al., 2012). Nsp3, together with 3C-like 
protease, is responsible for the replication of genomic RNA. 
The activity of nsp3 is attributed to the presence of a 316 
amino acid catalytic triad domain consisting of cysteine, 
histidine, and aspartic acid residues (Lindner et al., 2005). 
Recognition of the substrate by nsp3 is guided by the presence 
of a recognition site made up of LXGG or its homolog LRGG 
site (Lindner et al., 2005). Just like nsp1, nsp3 suppresses host 
immunity by indirectly impeding the induction of type I 
interferon (IFN) through inhibition of IRF3 phosphorylation 
(Matthews, 2014). IFN3 is a regulator of cellular responses 
and an essential component for innate immunity. The 
inhibition IFN3 is linked to the de-ubiquitination (DUB) 
activity of nsp3 which suggests this as one of the mechanisms 
by which the virus modulates the host cellular activities 
(Lindner et al., 2005; Ratia et al., 2008). 
Due to the indispensable roles played by PLpro, 
several efforts have been made to target this protein. Ratia et 
al., (2008) screened up to 50000 compounds against PLpro in 
Vero E6 cells and identified a compound (GRL0617) with the 
ability to inhibit the protein by binding within the S4-S3 
subsites of the nsp3 and inducing a loop closure that halts its 
catalysis without any cytotoxicity. Equally, in silico docking 
study by Arya et al., (2020) revealed sixteen FDA approved 
drugs, including formoterol (a bronchodilator ) and 
chloroquine (a conventional malaria drug) that were able to 
dock nsp3. Equally, computational analysis of existing 
antiviral regimens such as thymidine and ribavirin, natural 
phytochemicals including epigallectin, tanshinones, 
diarylheptanoids, geranylated flavonoids as well as 
antibacterial compounds (chloramphenicol and cefamandole) 
have shown a high binding affinity to PLpro (Wu et al., 2020).  
 
Viral 3-chymotrypsin-like cysteine protease (3CLPRO): 
3CLPRO, an approximately 33.1kDa protease, is involved in 
the control of activities under the virus replication complex. 
The protein works in tandem with PLpro in cleavage of the C-
terminus of replicase polyprotein at 11 sites through their 
catalytic site, which is defined by the presence of His41 and 
Cys145 (Wu et al., 2020). Besides the role in processing the 
viral polyprotein, PLpro has also been associated with 
shedding ubiquitin and Interferon-stimulated gene 15 (ISG15) 
from host-cell proteins. This allows the viruses to evade the 
host innate immune responses (Narayanan et al., 2008). As a 
drug target, 3CLPRO offers more advantages than the other 
viral proteins in that inhibiting it not only disrupts the 
replication ability of the virus but also sensitizes it to the host 
immunity. In a study to identify the potential active site of this 
protein, Bacha et al., (2004) discovered the presence of 
subsites containing serine residues at positions 139, 144, and 
147 that can be targeted by boronic acid-containing 
compounds. This observation on the ability of a boron-
containing compound to inhibit proteases is also supported by 
Soriano-Ursua, (2020) findings on inhibition of SARS-CoV-2 
main protease. 
 
RNA-dependent RNA polymerase (RdRp): RdRp, a non-
structural protein encoded at position 12 (nsp12) of the pab1 
polyprotein, is among the essential protease in coronaviruses 
and act as a core enzyme in both replication and translation of 
the viral genetic material (Zumla, 2016). Unlike other viruses, 
coronavirus encodes a proofreading mechanism in nsp14 
protein, which aids the RdRp in conferring a relatively higher 
fidelity replication compared to other viruses. The requisite 
role of RdRp in replication of the viral RNA genome makes it 
a desirable candidate for the development of coronavirus 
drugs. Indeed, several drugs are in the trial stage against RdRp 
in coronaviruses. Among these drugs is Remdesivir (RDV), a 
nucleotide analog inhibitor of RdRp, which has a broad 
spectrum of antiviral activities against several RNA viruses 
(Gordon et al., 2020). Even though this is not yet proven 
experimentally, it is proposed that the RDV competes with 
ATP by binding to the region of the protein leading to the 
arrest of RNA synthesis and, subsequently, delayed transcript 
(mRNA) chain termination. A culture-based experiment on 
the effects of aurintricarboxylic acid (ATA) on the replication 
of SARS-CoV demonstrated a significantly reduced viral 
mRNA (up to 1000-fold less) for cells treated with ATA. A 
comparison of this drug potency to interferons demonstrated a 
10fold higher performance (He et al., 2004). 
Spike protein(S): Following the Polyprotein ab1 is the spike 
glycoprotein(S), also called surface glycoprotein whose role is 
in interaction with the host ACE-2 receptors during infection 
and acts as the basic necessity for the entry of coronavirus into 
the host cell (Zumla et al., 2009). Studies in murine 
coronavirus mouse hepatitis virus revealed the size of this 
protein to be approximately 180kDa and are cleaved post-
translationally into S1 and S2 proteins. Binding of the virus to 
the host receptor is achieved through the S1 subunit, while S2 
is believed to contain internal fusion peptides that are involved 
in the fusion of the viral and host membranes.  As a drug 
target, antiviral drugs against other enveloped viruses such as 
the hepatitis C virus were shown by computational methods as 
potent inhibitors for S-proteins (M.S.H.J.G.T.E, 2020). These 
drugs include paritaprevir, grazoprevir, velpatasvir, and 
simeprevir. 
The bottom line on the applicability of SARS-CoV-2 
proteins as drug targets: Viruses are prone to mutations, and 
this is expected for coronaviruses with a more accelerated 
evolutionary rate as they are single-stranded RNA viruses. 
Efforts in developing drugs targeting such viruses or their 
proteins often end up becoming futile despite the promising 
potential. With this in mind, we aligned the amino acid 
sequences of the reviewed proteins from three different, 
random isolates of SARS-CoV-2 collected in different 
timespan as well as two viruses belonging to coronavirus 
family to test their similarity. From the alignment, it is clear 
that the amino acid residues for these proteins are relatively 
conserved within the SARs human isolates and Bat SARs 
coronavirus (Fig. 4). This is, however, not true for the Middle 
East respiratory syndrome coronavirus (MERS-CoV) where 
clear differences from other coronaviruses can be seen. With 
this evidence, spike, 3CLpro, envelope, and PLpro can serve 
as useful candidates for the development of drugs/inhibitors 
against SARS coronavirus. 
Epidemiology of Covid-19 and progress in control measures 
7 Afr. J. Biomed. Res. Vol. 24, No.1 (January) 2021  Birindwa et al 
 
 
Figure 4:  
A snapshot of amino acids alignment of six different isolates including Wuhan 2020 or SARS-CoV-2 (AY278554), USA 2014 
or SARS-CoV-2 (KF514389), Italy 2020 or SARS-CoV-2 (MT066156), Bat coronavirus 2013 (PDB: P0C6W2), and MERS 
coronavirus 2020 (PDB: T2B9I2). The left panel shows the accession of the strains used for this comparison. For the aligned 
proteins, PLpro, Spike, RdRp and nsp1, negligible differences in amino acid sequences is clear between the isolates with an 
exception of MERS. (Wu et al., 2020).     
 
Prospect of developing a SARS vaccine: The progress that 
is perhaps being closely monitored is the development of a 
COVID-19 vaccine. Designing a safe vaccine for a new illness 
is no easy feat. Thankfully, rapid progress is being made for a 
variety of reasons, including China’s efforts in sequencing 
Sars-CoV-2 genome and global sharing of information among 
the research groups. SARS and MERS’ etiological agents are 
coronaviruses and even though vaccines were shelved once 
previous outbreaks were contained, lessons can still be drawn 
from them.  Despite the several efforts made to contain CoV 
infections, the extensive sequence diversity (Graham et al., 
2013) of the causative agents renders them futile. It is however 
encouraging that most of the previous therapeutic options that 
are promising in the management of COVID-19 are based on 
previous experiences in treating SARS- and MERS-CoV 
(Kuldeep, 2020).  
 The use of next-generation sequencing and reverse 
genetics may also reduce the development time of more 
conventional vaccines during epidemics. A more complete 
and continually updated list is available from the World 
Health Organization (WHOc, 2020). First, although the 
virus’s spike protein is a promising immunogen for protection, 
optimizing antigen design is critical to ensure optimal immune 
response. Debate continues over the best approach for 
example, targeting the full-length protein or only the receptor-
binding domain. Second, preclinical experience with vaccine 
candidates for SARS and the Middle East respiratory 
syndrome (MERS) has raised concerns about exacerbating 
lung disease, either directly or as a result of antibody-
dependent enhancement. Such an adverse effect may be 
associated with a type 2 helper T-cell (Th2) response (Chen et 
al., 2020).  
 Multiple strategies are adopted in the development of 
CoV vaccines; most of this target the surface-exposed spike 
(S) glycoprotein or S protein as the major inducer of 
neutralizing antibodies. Several S-protein-based strategies 
have been attempted for developing CoV vaccines, e.g., use of 
full-length S protein or S1receptor-binding domain (RBD) and 
expression in virus-like particles (VLP), DNA, or viral vectors 
with the S protein molecule containing two subunits, S1 and 
S2 (Graham et al., 2013). The first subunit has an RBD that 
interacts with its host cell receptor, angiotensin-converting 
enzyme 2 (ACE2), whereas the S2 subunit mediates fusion 
between the virus and host cell membranes for releasing viral 
RNA into the cytoplasm for replication. It has been shown that 
the C-terminal domain of the S1 subunit of porcine Delta 
coronavirus constitutes the immunodominant region, and the 
immune response to this region shows the most potent 
neutralizing effect (Chen et al., 2020).  Despite the high 
genetic similarity between SARS-CoV-2 and SARS-CoV, the 
possibility of developing a universal CoV vaccine was 
performed and assessed based on the similarity in T-cell 
epitopes of SARS and MERS-CoV that confirmed the 
potential for cross-reactivity among CoVs. Thus vaccines 
developed for SARS-CoV may probably exhibit cross-
reactivity to SARS-CoV-2.The comparative evaluation 
performed on full-length S protein sequences of SARS-CoV-
2 and SARS-CoV identified that the most variable residues 
were located in the S1 subunit of S protein, the critical CoV 
vaccine target (Li et al., 2020; Chen et al., 2020). The NIAID-
VRC scientists are developing a vaccine candidate expressing 
SARS-CoV-2 S protein in the mRNA vaccine platform 
technology. 
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Future prospects: Achievements in the development of 
vaccines and therapeutic agents for SARS- and MERS-CoV, 
as well as ongoing progress for COVID-19, will facilitate the 
development of effective vaccines and therapeutics against 
this emerging virus (Hopman, 2020). However, the present 
scenario of COVID-19 warrants the need for implementing 
robust preventive and control measures due to the potential for 
nosocomial infections. Results obtained from the recently 
conducted in vitro study against COVID-19 are promising 
since the drugs remdesivir and chloroquine were found to be 
highly effective in controlling the infection (El Bcheraoui et 
al., 2020). Although research is in progress to improve 
prevention, treatment, and control of COVID-19, the 
documented clinical data on different therapeutic approaches 
for CoVs are scarce. Further research should be directed 
toward the study of SARS-CoV-2 in suitable animal models 
for analyzing replication, transmission, and pathogenesis 
(Chin et al., 2020). The assessment of health and socio-
economic impacts of this pandemic. 
 
CONCLUSION 
The coronavirus disease 19 (COVID-19) is a highly 
contagious and lethal viral disease caused by SARS-CoV-2 
and originated from Wuhan, China which has spread over the 
world. Genetic analysis showed that SARS-CoV-2 is 
genetically related to severe acute respiratory syndrome-like 
(SARS-like) bat viruses suggesting that bats could be potential 
primary reservoir. To date, no effective treatment or 
prevention is available against human coronaviruses. 
However, research are ongoing to develop efficient preventive 
and therapeutic measures to get through with the novel 
coronaviruses. Nevertheless, little clinical trials on antiviral 
drugs against COVI-19 have been performed and resulted in 
some clinical recoveries. In addition, there are currently 
several companies working for the development of efficient 
SARS-CoV-2 vaccines bust still will undergo human and 
animal-based trails before commercialization. Efforts on 
targeting vaccines and antiviral drugs for human coronavirus 
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